Compare MDGL & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDGL | TFX |
|---|---|---|
| Founded | 2011 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 4.8B |
| IPO Year | N/A | N/A |
| Metric | MDGL | TFX |
|---|---|---|
| Price | $603.00 | $122.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 10 |
| Target Price | ★ $580.77 | $139.88 |
| AVG Volume (30 Days) | 325.9K | ★ 778.8K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 1.09% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $740,640,000.00 | ★ $3,189,988,000.00 |
| Revenue This Year | $436.04 | $9.90 |
| Revenue Next Year | $53.17 | $10.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 864.21 | 5.42 |
| 52 Week Low | $265.00 | $102.58 |
| 52 Week High | $609.98 | $185.94 |
| Indicator | MDGL | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 66.27 | 50.08 |
| Support Level | $535.33 | $121.76 |
| Resistance Level | $609.98 | $126.13 |
| Average True Range (ATR) | 20.86 | 3.88 |
| MACD | -0.56 | -0.11 |
| Stochastic Oscillator | 93.68 | 20.30 |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.